Anika Therapeutics Inc. - Common Stock (ANIK)

Anika (ANIK) Q1 2026 Earnings Transcript

Anika (ANIK) Q2 2025 Earnings Call Transcript

Anika (ANIK) Q4 2025 Earnings Call Transcript

CANTON, Mass. — In a milestone development for the regenerative medicine sector, Organogenesis Holdings Inc. (Nasdaq: ORGO) announced today that it has successfully concluded a pivotal Type B meeting with the U.S. Food and Drug Administration (FDA), cementing its plans to finalize the Biologics License Application (BLA) for ReNu, its

Anika (ANIK) Q3 2025 Earnings Call Transcript

Anika Therapeutics (ANIK) beat Q3 2025 earnings estimates with a profit of $0.04 per share, driving its stock up over 10% despite a slight revenue miss.

Anika Therapeutics reported mixed Q2 2025 results, with revenue beating estimates but EPS missing. Shares fell 9% amid Hyalofast trial concerns despite strong regenerative solutions growth.

U.S. stock futures fell again on Thursday after a brief respite on Wednesday, following a softer-than-expected inflation print.

ANIK stock results show that Anika Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

ANIK stock results show that Anika Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.